ReviewInternational journal of molecular sciences2019
Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Melatonin Ameliorates Isoproterenol-Induced Cardiac Fibrosis by Suppressing BIP/PERK/CHOP Signaling Pathways; Insights from In Silico and In vivo Studies.Cell biochemistry and biophysics · 2025Article
- Circadian Rhythm Disruptions and Cardiovascular Disease Risk: The Special Role of Melatonin.Current issues in molecular biology · 2025Review
- Microbial melatonin metabolism in the human intestine as a therapeutic target for dysbiosis and rhythm disorders.NPJ biofilms and microbiomes · 2024Review
- Comprehensive review of melatonin as a promising nutritional and nutraceutical supplement.Heliyon · 2024Review
- Cardiac-targeted delivery of nuclear receptor RORα via ultrasound targeted microbubble destruction optimizes the benefits of regular dose of melatonin on sepsis-induced cardiomyopathy.Biomaterials research · 2023Article
- Multiplatform-Integrated Identification of Melatonin Targets for a Triad of Psychosocial-Sleep/Circadian-Cardiometabolic Disorders.International journal of molecular sciences · 2023Article
- Insights about circadian clock in glioma: From molecular pathways to therapeutic drugs.CNS neuroscience & therapeutics · 2022Review
- ECG Markers of Acute Melatonin Treatment in a Porcine Model of Acute Myocardial Ischemia.International journal of molecular sciences · 2022Article
- Melatonin and the Brain-Heart Crosstalk in Neurocritically Ill Patients-From Molecular Action to Clinical Practice.International journal of molecular sciences · 2022Review
- Effects of berbamine against myocardial ischemia/reperfusion injury: Activation of the 5' adenosine monophosphate-activated protein kinase/nuclear factor erythroid 2-related factor pathway and changes in the mitochondrial state.BioFactors (Oxford, England) · 2022Article
- Revisiting the role of melatonin in human melanocyte physiology: A skin context perspective.Journal of pineal research · 2022Review
- Role of the Antioxidant Activity of Melatonin in Myocardial Ischemia-Reperfusion Injury.Antioxidants (Basel, Switzerland) · 2022Review
- Women with polycystic ovary syndrome (PCOS) have reduced melatonin concentrations in their follicles and have mild sleep disturbances.BMC women's health · 2022Article
- New insights into the role of melatonin in diabetic cardiomyopathy.Pharmacology research & perspectives · 2022Review
- Melatonin Reduces Oxidative Stress in the Right Ventricle of Newborn Sheep Gestated under Chronic Hypoxia.Antioxidants (Basel, Switzerland) · 2021Article
- [Melatonin alleviates myocardial ischemia-reperfusion injury in mice by inhibiting inflammatory responseNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Anti-Inflammatory Activity of Melatonin: a Focus on the Role of NLRP3 Inflammasome.Inflammation · 2021Review
- Melatonin as a Reducer of Neuro- and Vasculotoxic Oxidative Stress Induced by Homocysteine.Antioxidants (Basel, Switzerland) · 2021Review
- Article
- Effect of melatonin on heart failure: design for a double-blinded randomized clinical trial.ESC heart failure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In this review we summarized the actual clinical data for a cardioprotective therapeutic role of melatonin, listed melatonin and its agonists in different stages of development, and evaluated the melatonin cardiovascular target tractability and prediction using machine learning on ChEMBL. To date, most clinical trials investigating a cardioprotective therapeutic role of melatonin are in phase 2a. Selective melatonin receptor agonists Tasimelteon, Ramelteon, and combined melatonergic-serotonin Agomelatine, and other agonists with registered structures in CHEMBL were not yet investigated as cardioprotective or cardiovascular drugs. As drug-able for these therapeutic targets, melatonin receptor agonists have the benefit over melatonin of well-characterized pharmacologic profiles and extensive safety data. Recent reports of the X-ray crystal structures of MT1 and MT2 receptors shall lead to the development of highly selective melatonin receptor agonists. Predictive models using machine learning could help to identify cardiovascular targets for melatonin. Selecting ChEMBL scores > 4.5 in cardiovascular assays, and melatonin scores > 4, we obtained 284 records from 162 cardiovascular assays carried out with 80 molecules with predicted or measured melatonin activity. Melatonin activities (agonistic or antagonistic) found in these experimental cardiovascular assays and models include arrhythmias, coronary and large vessel contractility, and hypertension. Preclinical proof-of-concept and early clinical studies (phase 2a) suggest a cardioprotective benefit from melatonin in various heart diseases. However, larger phase 3 randomized interventional studies are necessary to establish melatonin and its agonists' actions as cardioprotective therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.